Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
If GLP-1 agonists like semaglutide and tirzepatide can safely reduce cravings for substances, they could provide a strong new choice for treating Alcohol Use Disorder (AUD), which currently has few medication options
( Epub 2024 Jul 25 PMID: 39098289 )
Understanding these patterns helps patients push through the difficult early period of either medication without abandoning treatment prematurely
To help overcome this limitation, our work focused on integrating data from multiple sources, including genetics, as well as complex signatures rather than individual proteins
The GLP-1 consumer is maturing into a recognizable mainstream demographic
